Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,014 public trials 2,030 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment

NCT02977494

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Charité Universitätsmedizin BerlinCampus Benjamin Franklin Berlin, Germany
  • Vivantes Klinikum Neukölln Berlin, Germany
  • Klinikum Chemnitz GmbH Chemnitz, Germany
  • Katholische Karl-Leisner Klinikum Goch Goch, Germany
View Trial Details
Completed

Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)

NCT00042341

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Children's Hospital Los Angeles, California, United States
  • Children's Hospital Orange County, California, United States
  • Children's Hospital San Diego, California, United States
  • Children's Hospital Denver, Colorado, United States
View all 14 locations
View Trial Details
Completed

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

NCT03365791

Conditions
Adenocarcinoma Of Esophagus, Advanced Well-differentiated Neuroendocrine Tumors, Bronchial Neoplasms, +28 more
Locations
  • California Pacific Medical Center Drug Shipment (2) San Francisco, California, United States
  • Hematology Oncology Associates of the Treasure Coast Port Saint Lucie, Florida, United States
  • University Cancer and Blood Center, LLC Athens, Georgia, United States
  • Northwestern University Medical School Chicago, Illinois, United States
View all 20 locations
View Trial Details
Completed

Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma

NCT03029234

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Beijing Chao Yang Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Sun Yat-Sen University Cancer Center Guangzhou, Guangdong, China
View all 17 locations
View Trial Details
Completed

Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL

NCT02419560

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • City of Hope Duarte, California, United States
  • Winship Cancer Institute, Emory University Atlanta, Georgia, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • University of Virginia Charlottesville, Virginia, United States
View Trial Details
Completed

Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma

NCT02197221

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Clinique Universitaire Saint Luc Brussels, Belgium
  • Grand Hôpital de Charleroi - Site Notre-Dame Charleroi, Belgium
  • Chu Liege Liège, Belgium
  • CHU Dinant-Godinne UCL Namur Yvoir, Belgium
View all 46 locations
View Trial Details

Related conditions